Development of a Bioluminescent Cell-Based Assay to ... - Promega

More documents

Recommendations

Info

ADCC Reporter Bioassay is robust Fold of Induction Fold of Induction 30 20 10 0 -10 -9 -8 -7 -6 -5 Log10 [B1 antibody], g/ml 30 20 10 1 0 -10 -9 -8 -7 -6 -5 Log10 [B1 antibody], g/ml Confidential and Proprietary. Not for Further Disclosure. Time of induction 1 6 7 14 1 7 13 16 Run Hr induction EC50 1 6 hr 3.15 x 10e-8 g/ml 2 5.5 hr 3.83 x 10e-8 g/ml E:T ratio and cells/well Run E:T ratio T cells E cells EC50 1 7.5:1 10K 75K 3.09 x 10e-8 g/ml 2 6:1 15K 90K 3.83 x 10e-8 g/ml
Additional target cell option: Raji cells Frozen, thaw-and-use FcgRIIIa/NFAT-luc2 Effector Cells (75K per well) Confidential and Proprietary. Not for Further Disclosure. Raji cells/well 21
Page 1 and 2: Development of a Bioluminescent Cel
Page 3 and 4: Signaling pathways activated in eff
Page 5 and 6: Protocol 1. Reference or test antib
Page 7 and 8: FcgRIIIa antibody blocking of ADCC
Page 9 and 10: Bioassay development: Optimizing Ef
Page 11 and 12: Bioassay development: Evaluating cl
Page 13 and 14: Target cells can also be frozen, th
Page 15 and 16: ADCC Reporter Bioassay using frozen
Page 17 and 18: Precision, accuracy and linearity o
Page 19: ADCC Reporter Bioassay is stability
Page 23 and 24: iological activity of therapeutic a
Page 25 and 26: Planned ADCC Reporter Bioassay kit
Page 27: For more information Confidential a

Development of a Bioluminescent Cell-Based Assay to ... - Promega

Create successful ePaper yourself

Delete template?

Save as template?